In this issue:
Transplant in MM patients with renal insufficiency
Tocilizumab shows promise for COVID-19 treatment in patients with haematological disorders
Therapies for monoclonal gammopathy-associated scleromyxedema
Once-weekly carfilzomib in RRMM
Bortezomib-based consolidation or
maintenance therapy for MM
Genetic predisposition for MM
Subcutaneous daratumumab comparable to intravenous
Obese patients have an increased risk for bortezomib-induced peripheral neuropathy
Bortezomib versus lenalidomide triplet regimes for patients at first relapse
A liquid biopsy to detect multidrug resistance in MM
Please login below to download this issue (PDF)